Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label study of emicizumab prophylaxis on joint health, physical activity, and overall health in moderate or severe hemophilia A without FVIII inhibitors
2023-505747-40-00Phase 4Completed
- Sponsor
- Roche
- Start
- Apr 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Primary endpoints: Joint status over time by HEAD-US, Clinical joint status by HJHS v2.1 and 9 more. Started Apr 2022; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2023-505747-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505747-40-00.